<DOC>
	<DOCNO>NCT00442039</DOCNO>
	<brief_summary>This clinical trial perform Best Pharmaceuticals Children Act , sign law 2002 order improve pediatric label off-patent drug . The purpose study examine efficacy safety lithium treatment pediatric patient bipolar I disorder .</brief_summary>
	<brief_title>Lithium Treatment Pediatric Mania</brief_title>
	<detailed_description>This multiphase , multicenter , trial comprehensively examine lithium treatment pediatric patient bipolar I disorder . In order examine treatment bipolar disorder lithium , study include four phase treatment . The first phase , Pharmacokinetic Phase , include 8 week Open Label treatment determine empirically base dosing strategy child adolescent bipolar disorder . Patients complete Pharmacokinetic Phase , may eligible continue Long-Term Effectiveness Phase maximum 16 week lithium treatment . Subsequently , patient meet response criterion Long-Term Effectiveness Phase eligible continue Discontinuation Phase . During Discontinuation Phase , patient randomize either placebo lithium treatment 28 week . Finally , subject experience mood relapse Discontinuation Phase enrol Open Label Restabilization Phase treat lithium 8 week .</detailed_description>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>1 . The patient age 7 year 17 year , 11 month time first dose . 2 . The patient meet DSMIV diagnostic criterion , assess semistructured assessment ( Kiddie Schedule Affective Disorders Schizophrenia Present Lifetime [ KSADSPL ] ) separate clinical interview child/adolescent psychiatrist manic mixed episode Bipolar I disorder . 3 . The patient score ≥ 20 YMRS screen baseline . 4 . The patient legal guardian understood nature study able comply protocol requirement . The legal guardian give write informed consent youth , write assent . 5 . Patients comorbid condition ( attention deficit hyperactivity disorder [ ADHD ] , conduct disorder ) eligible participate . 6 . If female : patient premenarchal , incapable pregnancy hysterectomy , tubal ligation , spousal/partner sterility . If sexually active capable pregnancy , patient must use acceptable method contraception ( hormonal contraceptive , intrauterine device , spermicide barrier ) least 1 month prior study entry agree continue use one duration study . If sexually abstinent capable pregnancy , patient agree continue abstinence use acceptable method birth control ( either intrauterine device spermicide barrier ) sexual activity commence . 7 . If female , patient negative quantitative serum ßhuman chorionic gonadotrophin hormone pregnancy test screen negative qualitative urine pregnancy test baseline , female . 8 . Patients history substance abuse eligible participate agree continue abstain drug trial negative drug screen screen prior baseline . 9 . The patient willing clinically able washout ( approximately 5 halflives ) exclusion medication screen period prior administration lithium . ( No stable patient ask discontinue medication . ) 10 . The patient‟s ECG blood work ( include complete blood count [ CBC ] , electrolytes , etc . ) show clinically significant abnormality . 1 . The patient clinically stable current medication regiment bipolar disorder . 2 . The patient current lifetime diagnosis Schizophrenia Schizoaffective Disorder , Pervasive Developmental Disorder ( Austin Screening Questionnaire score &gt; 15 ) , Anorexia Nervosa , Bulimia Nervosa , ObsessiveCompulsive Disorder . 3 . The patient current DSMIV diagnosis Substance Dependence . 4 . The patient positive drug screen screen retest 13 week later . 5 . The patient symptom mania may attributable general medical condition , secondary use medication ( eg , corticosteroid ) 6 . The patient evidence serious and/or unstable neurological illness treatment auspex study would contraindicate . 7 . The patient serious , unstable medical illness clinically significant abnormal laboratory assessment would adversely impact scientific interpretability unduly increase risk protocol . 8 . The patient current general medical condition include neurological disease , diabetes mellitus , thyroid dysfunction , renal dysfunction might affect adversely lithium , could influence efficacy safety lithium , would complicate interpretation study result . 9 . The patient evidence current serious homicidal/suicidal ideation treat physician 's opinion appropriately safe patient participate study . 10 . The patient evidence current active hallucination delusion treat physician 's opinion appropriately safe patient participate study . 11 . The patient concomitant prescription overthecounter medication nutritional supplement would interact lithium patient‟s physical mental status . 12 . The patient use psychotropic agent stimulant within precede 2 week , include antipsychotic , monoamine oxidase inhibitor , antidepressant ; use stimulant within precede week ; fluoxetine depot antipsychotic within past month . 13 . The patient current psychotherapy treatment provide outside study initiate within 4 week prior screen . 14 . The patient previous adequate trial lithium ( least 4 week lithium serum level 0.81.2 mEq/L ) . 15 . The patient history allergy lithium . 16 . The patient psychiatric hospitalization within 1 month screen psychosis serious homicidal/serious suicidal ideation . 17 . Clinician‟s judgment patient likely able complete study outpatient due psychiatric reason . 18 . The patient history lithium intolerance . 19 . Females currently pregnant lactate . 20 . Sexually active female , investigators‟ opinion , use adequate form birth control . 21 . Patients unable swallow study medication . 22 . Patients baseline YMRS score &lt; 20 anticipate . 23 . Patients IQ &lt; 70 ( determine use Wechsler Abbreviated Scales Intelligence [ WASI ] Vocabulary Matrix Reasons Subscales ) .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Mania , Lithium , Bipolar , BPCA , pediatrics</keyword>
</DOC>